Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 10/20 | 0.53 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.53 |
| ▸ | ALK | Q9UM73 | 10/20 | 0.49 |
| ▸ | NPM1 | P06748 | 5/20 | 0.49 |
| ▸ | INSR | P06213 | 3/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL522655 | 0.88 | JAK2 (0.53) | JAK2PTK2ALKNPM1INSR | |
| SCHEMBL519742 | 0.81 | ALK (0.56) | JAK2PTK2ALKNPM1INSR | |
| SCHEMBL521136 | 0.80 | JAK2 (0.39) | JAK2PTK2ALKNPM1INSR | |
| SCHEMBL520719 | 0.79 | ALK (0.41) | JAK2PTK2ALKNPM1INSR | |
| SCHEMBL520690 | 0.73 | JAK2 (0.42) | JAK2PTK2ALKNPM1INSR | |
| SCHEMBL521048 | 0.73 | JAK2 (0.52) | JAK2PTK2ALKNPM1INSR | |
| SCHEMBL522173 | 0.72 | JAK2 (0.49) | JAK2PTK2ALKNPM1INSR | |
| SCHEMBL522157 | 0.71 | ALK (0.43) | JAK2PTK2ALKNPM1INSR | |
| SCHEMBL520325 | 0.70 | ALK (0.79) | JAK2PTK2ALKNPM1INSR | |
| SCHEMBL519833 | 0.67 | JAK2 (0.45) | JAK2PTK2ALKNPM1INSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | JAK2 1/4885PTK2 592/4885ALK 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.